An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

@article{Patel2009AnIA,
  title={An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.},
  author={Keyur A. Patel and Yves Benhamou and Eric M Yoshida and Kelly D E Kaita and Stefan Zeuzem and Michael S. Torbenson and Erik Pulkstenis and G. M. Subramanian and John McHutchison},
  journal={Journal of viral hepatitis},
  year={2009},
  volume={16 3},
  pages={178-86}
}
SUMMARY Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE and FIBROSpect II) during interferon-based therapy. Ninety-five interferon-naïve patients with genotype 1 CHC were enrolled in a phase 2b, active-controlled study of albinterferon alfa-2b/ribavirin for 48 weeks… CONTINUE READING
29 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…